Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 3/20 | 0.41 |
| ▸ | CPT2 | P23786 | 1/20 | 0.32 |
| ▸ | ACLY | P53396 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL966173 | 0.98 | CA4 (0.43) | CA4CPT2ACLY | |
| Potassium Ion SCHEMBL337213 | 0.98 | CA4 (0.43) | CA4CPT2ACLY | |
| Potassium Ion SCHEMBL2466395 | 0.96 | CA4 (0.41) | CA4CPT2ACLY | |
| Potassium Ion SCHEMBL6442487 | 0.96 | CA4 (0.41) | CA4CPT2ACLY | |
| SCHEMBL2706202 | 0.96 | CA4 (0.41) | CA4CPT2ACLY | |
| Water SCHEMBL2956339 | 0.96 | CA4 (0.41) | CA4CPT2ACLY | |
| SCHEMBL6444193 | 0.96 | CA4 (0.41) | CA4CPT2ACLY | |
| Potassium Ion SCHEMBL29489145 | 0.96 | CA4 (0.41) | CA4CPT2ACLY | |
| Potassium Ion SCHEMBL1767658 | 0.96 | CA4 (0.41) | CA4CPT2ACLY | |
| SCHEMBL1460547 | 0.94 | CA4 (0.43) | CA4CPT2ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216314-A1 | METHODS AND PHARMACEUTICAL PREPARATIONS FOR ELEVATING KETONE UTILIZATION | GLYKON TECHNOLOGIES GROUP, LLC | 2024-07-04 | — | — | US | disclosed |
| US-11957649-B2 | Methods and pharmaceutical preparations for elevating ketone utilization | GLYKON TECHNOLOGIES GROUP, LLC (US) | 2024-04-16 | — | — | US | disclosed |
| US-11766415-B2 | Reducing triglyceride levels and cortisol levels with pharmaceutical preparations | GLYKON TECHNOLOGIES GROUP, LLC (US) | 2023-09-26 | — | — | US | disclosed |
| EP-4157254-A1 | METHODS AND PHARMACEUTICAL PREPARATIONS FOR ELEVATING KETONE UTILIZATION | Glykon Technologies Group, LLC. (US) | 2023-04-05 | — | — | EP | disclosed |
| EP-4157199-A1 | METHODS AND PHARMACEUTICAL PREPARATIONS FOR ELEVATING BLOOD HEMOGLOBIN AND OXYGEN SATURATION LEVELS WITH HYDROXYCITRIC ACID | Glykon Technologies Group, LLC (US) | 2023-04-05 | — | — | EP | disclosed |
| EP-4156970-A1 | REDUCING TRIGLYCERIDE LEVELS AND CORTISOL LEVELS WITH PHARMACEUTICAL PREPARATIONS | Glykon Technologies Group, LLC. (US) | 2023-04-05 | — | — | EP | disclosed |
| US-11219610-B2 | Bolus dose of hydroxycitric acid with glycerol | GLYKON TECHNOLOGIES GROUP, LLC (US) | 2022-01-11 | — | — | US | disclosed |
| US-20200206171-A1 | Bolus Dose of Hydroxycitric Acid with Glycerol | GLYKON TECHNOLOGIES GROUP, LLC (US) | 2020-07-02 | — | — | US | disclosed |
| US-20200138767-A1 | HYDROXYCITRIC ACID COMPOUNDS AND CAPSULE LIQUID DELIVERY | GLYKON TECHNOLOGIES GROUP, LLC (US) | 2020-05-07 | — | — | US | disclosed |
| US-10624868-B2 | Bolus dose of hydroxycitric acid with glycerol | GLYKON TECHNOLOGIES GROUP, LLC (US) | 2020-04-21 | — | — | US | disclosed |
| US-9789076-B2 | Bolus dose of hydroxycitric acid with glycerol | GLYKON TECHNOLOGIES GROUP, LLC (US) | 2017-10-17 | — | — | US | disclosed |
| US-20160136117-A1 | BOLUS DOSE OF HYDROXYCITRIC ACID WITH GLYCEROL | NUTRITION RESEARCH GROUP, LIMITED (GB) | 2016-05-19 | — | — | US | disclosed |
| EP-2445338-A1 | SYNERGISTIC COMBINATION TO ENHANCE BLOOD GLUCOSE AND INSULIN METABOLISM | Glykon Technologies Group, Llc. (US) | 2012-05-02 | — | — | EP | disclosed |
| WO-2010150072-A1 | SYNERGISTIC COMBINATION TO ENHANCE BLOOD GLUCOSE AND INSULIN METABOLISM | GLYKON TECHNOLOGIES GROUP, LLC. (US) | 2010-12-29 | — | — | WO | disclosed |
| US-20100323031-A1 | Synergistic combination to enhance blood glucose and insulin metabolism | GLYKON TECHNOLOGIES GROUP, LLC (US) | 2010-12-23 | — | — | US | disclosed |
| US-20080293815-A1 | HCA FOR IMPROVED HDL SERUM LIPIDS PROFILE | GLYKON TECHNOLOGIES GROUP, LLC | 2008-11-27 | — | — | US | disclosed |
| WO-2008048574-A2 | HCA FOR IMPROVED HDL SERUM LIPIDS PROFILE | CLOUATRE DALLAS (US) | 2008-04-24 | — | — | WO | disclosed |
| US-20060025482-A1 | (-)-Hydroxycitric acid for the modulation of angiotensin-converting enzyme | CLOUATRE DALLAS L | 2006-02-02 | — | — | US | disclosed |
| US-20060025483-A1 | (-)-Hydroxycitric acid for protection against soft tissue and arterial calcification | CLOUATRE DALLAS L | 2006-02-02 | — | — | US | disclosed |
| US-20060025483-A1 | (-)-Hydroxycitric acid for protection against soft tissue and arterial calcification | CLOUATRE DALLAS L | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11766415-B2 | Reducing triglyceride levels and cortisol levels with pharmaceutical preparations | CETP, MTTP, HMGCR | CA4 1638/4885CPT2 74/4885ACLY 965/4885 |
| US-11957649-B2 | Methods and pharmaceutical preparations for elevating ketone utilization | PC, AK2, CPT2 | CA4 1500/4885CPT2 3/4885ACLY 103/4885 |
| US-20240216314-A1 | METHODS AND PHARMACEUTICAL PREPARATIONS FOR ELEVATING KETONE UTILIZATION | PC, AK2, CPT2 | CA4 1500/4885CPT2 3/4885ACLY 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.